PROK

SEC source: 0001140361-25-014211 · form4.xml · nonDerivative · entry 1

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,862,330

F1 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.71 to $0.74 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units

F4 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F5 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F6 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-25-013770 · form4.xml · nonDerivative · entry 2

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,594,225

F2 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6057 to $0.61 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F4 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F5 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F6 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-25-013770 · form4.xml · nonDerivative · entry 1

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,592,325

F1 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.575 to $0.61 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F3 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F4 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F5 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F6 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0000950170-25-032251 · ownership.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Class A Ordinary Shares · 450,000 shares

Expires 2035-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025.

SEC source: 0000950170-25-032255 · ownership.xml · derivative · entry 1

Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,796,000

Underlying: Class A Ordinary Shares · 1,796,000 shares

Expires 2035-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025.

SEC source: 0000950170-25-032249 · ownership.xml · derivative · entry 1

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Class A Ordinary Shares · 650,000 shares

Expires 2035-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025.

SEC source: 0000950170-25-032247 · ownership.xml · derivative · entry 1

Coulston James · CIK 0001936203 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Class A Ordinary Shares · 650,000 shares

Expires 2035-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025.

SEC source: 0000950170-25-015495 · ownership.xml · derivative · entry 4

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,107,426

Underlying: Class A Ordinary Shares · 532,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F5 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F5 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · derivative · entry 3

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,107,426

Underlying: Class A Ordinary Shares · 532,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (the "Common Units") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis.

F4 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F4 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,617,909

F2 · kind: Prior to February 4, 2025 (the "Transaction Date"), Tolerantia held 88,639,961 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 4,479,424 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 532,535 of the 4,479,424 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 532,535 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015495 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 23,150,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein.

SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 6

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust

Disclosed balance after: 675,235

Underlying: Class A Ordinary Shares · 675,234 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 5

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust

Disclosed balance after: 675,235

Underlying: Class A Ordinary Shares · 675,234 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each filed as an Issuer's Annual Report on Form 10-K filed on March 22, 2024), each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 4

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,929

Underlying: Class A Ordinary Shares · 81,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 3

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,929

Underlying: Class A Ordinary Shares · 81,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each filed as an Issuer's Annual Report on Form 10-K filed on March 22, 2024), each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-25-015369 · ownership.xml · nonDerivative · entry 2

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust

Disclosed balance after: 675,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-015369 · ownership.xml · nonDerivative · entry 1

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-108438 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,480

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-106912 · ownership.xml · derivative · entry 1

Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Ordinary Shares · 500,000 shares

Expires 2033-12-03

F1 · derivative.exercise_date: This performance-based stock option was granted on December 3, 2023. On September 13, 2024, the Company's board of directors certified achievement of the performance goal at 100%. In addition to the achievement of the performance goal, the options are subject to time vesting requirements under which 25% vested on September 13, 2024 and the remaining 75% vests in equal installments of 125,000 shares on each of November 15, 2024, February 15, 2025 and May 15, 2025.

SEC source: 0000950170-24-103630 · ownership.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,535

Underlying: Class A Ordinary Shares · 9,535 shares

Expires 2034-09-03

F1 · derivative.exercise_date: The option shall vest and become exercisable on July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date.

SEC source: 0000950170-24-089935 · ownership.xml · derivative · entry 3

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,857

Underlying: Class A Ordinary Shares · 81,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

SEC source: 0000950170-24-089935 · ownership.xml · derivative · entry 2

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,857

Underlying: Class A Ordinary Shares · 81,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis.

F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.

SEC source: 0000950170-24-089935 · ownership.xml · nonDerivative · entry 1

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-087273 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,892

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.51, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-075563 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,718

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.99, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-073633 · ownership.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · 10% owner

Tolerantia, LLC · CIK 0001937011 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,617,909

F1 · ownership.nature: Represents equity interests held by or for the benefit of Tolerantia, LLC, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia, LLC. Mr. Legorreta disclaims beneficial ownership of the equity interests held by or for the benefit of Tolerantia, LLC except to the extent of his indirect pecuniary interest therein.

SEC source: 0001140361-24-031298 · form4.xml · nonDerivative · entry 1

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,560,107

F1 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F2 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F3 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F4 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0000950170-24-068045 · ownership.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068072 · ownership.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068047 · ownership.xml · derivative · entry 1

Sinha Uma · CIK 0001742587 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068043 · ownership.xml · derivative · entry 1

Pereira Brian JG · CIK 0001298146 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068040 · ownership.xml · derivative · entry 1

Jimenez Santos Jose Ignacio · CIK 0001937007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068038 · ownership.xml · derivative · entry 1

DOYLE WILLIAM F · CIK 0001194459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-068034 · ownership.xml · derivative · entry 1

Lotvin Alan · CIK 0001472795 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,558

Underlying: Class A Ordinary Shares · 62,558 shares

Expires 2034-05-30

F1 · shares: These options were granted under the Issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

SEC source: 0000950170-24-063281 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,956

F1 · kind: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.74 to $4.44, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-046887 · ownership.xml · nonDerivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,194

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.53, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-046887 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,632

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.55, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-045248 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,432

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-044836 · ownership.xml · nonDerivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 189,670

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.77, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0000950170-24-040140 · ownership.xml · derivative · entry 1

Ernst Ulrich Peter Alfred · CIK 0002016924 · EVP, Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,000

Underlying: Class A Ordinary Shares · 335,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The option vests 25% on 1st anniversary of April 1, 2024 and the remaining 75% vests in substantially equal monthly installments for 36 months thereafter.

SEC source: 0000950170-24-044836 · ownership.xml · nonDerivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 273,773

F1 · ownership.direct: The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023.

SEC source: 0001140361-24-026549 · form4.xml · nonDerivative · entry 5

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,295,645

F5 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.4300 to $1.4399 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.

F6 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F7 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F8 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F9 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-24-026549 · form4.xml · nonDerivative · entry 4

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,265,645

F4 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.3800 to $1.4000 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

F6 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F7 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F8 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F9 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-24-026549 · form4.xml · nonDerivative · entry 3

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,251,645

F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.3890 to $1.4000 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

F6 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F7 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F8 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F9 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-24-026549 · form4.xml · nonDerivative · entry 2

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,218,645

F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.3550 to $1.3600 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F6 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F7 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F8 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F9 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0001140361-24-026549 · form4.xml · nonDerivative · entry 1

Control Empresarial de Capitales S.A. de C.V. · CIK 0001273693 · 10% owner · Add'l Rep. Persons-see Ex.99-1

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,168,645

F1 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $1.4900 to $1.5018 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F6 · balance_after: Includes 63,118,645 Class B Ordinary Shares, $0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.

F7 · balance_after: Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.

F8 · balance_after: One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.

F9 · ownership.direct: See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.

SEC source: 0000950170-24-025912 · ownership.xml · derivative · entry 2

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,264

Underlying: Class A Ordinary Shares · 117,264 shares

Expires 2034-03-01

F2 · derivative.exercise_date: The option vests 50% on the 1st anniversary of March 1, 2024 and the remaining 50% vests in substantially equal monthly installments for 12 months thereafter.

SEC source: 0000950170-24-025912 · ownership.xml · derivative · entry 1

Weber Darin J. · CIK 0001936228 · SVP of Regulatory Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Class A Ordinary Shares · 225,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2024.

SEC source: 0000950170-24-025919 · ownership.xml · derivative · entry 1

Coulston James · CIK 0001936203 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Class A Ordinary Shares · 275,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2024.

SEC source: 0000950170-24-025916 · ownership.xml · derivative · entry 2

Girolamo Todd C · CIK 0001891257 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,742

Underlying: Class A Ordinary Shares · 234,742 shares

Expires 2034-03-01

F2 · derivative.exercise_date: The option vests 50% on the 1st anniversary of March 1, 2024 and the remaining 50% vests in substantially equal monthly installments for 12 months thereafter.